MedPath

JAB-21822

Generic Name
JAB-21822
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
-
Background

JAB-21822 is an oral small-molecule KRAS G12C inhibitor.

Associated Conditions
-
Associated Therapies
-
globenewswire.com
·

KRAS Inhibitors Market: New Treatments Are Set to Change Cancer Care

The KRAS Inhibitors market is poised for significant growth driven by increasing cancer incidence, treatment access, and a robust pipeline. The market size in the 7MM was $500 million in 2023, expected to rise by 2034. KRAZATI (adagrasib) is projected to outperform LUMAKRAS (sotorasib) in revenue. The US leads in KRAS mutation cases in NSCLC, with 46% of 7MM cases. Competition in G12C NSCLC is intensifying, with Chinese biotechs entering the KRAS space. Despite G12D being the most prevalent KRAS variant, G12C is the primary target in colorectal cancer. KRAZATI is the first KRAS inhibitor approved for KRAS G12C-mutant colorectal cancer. Pancreatic cancer, with 60-90% KRAS mutations, presents a significant market opportunity. Pan-KRAS drugs, targeting multiple mutations, offer broad market potential. Key companies include Novartis, Roche, Genentech, and Mirati Therapeutics. Emerging therapies like JDQ443, Divarasib, and Avutometinib are expected to reshape the market. The KRAS inhibitor market is evolving, driven by high unmet needs, competitive drug development, and regulatory approvals.
nature.com
·

Recent advances in targeting the “undruggable” proteins

Covalent inhibitors bind to target proteins via covalent bonds, offering sustained inhibition and longer residence times compared to non-covalent inhibitors. They are effective against undruggable proteins and mutated kinases, exemplified by nirmatrelvir in COVID-19 treatment and sotorasib for KRASG12C mutations. Covalent inhibitors like sotorasib and adagrasib have shown promise in treating cancers with KRAS mutations, overcoming resistance and expanding therapeutic options.

Related Clinical Trials:

© Copyright 2025. All Rights Reserved by MedPath